Q4 2024 Penumbra Inc Earnings Call Transcript
Key Points
- Penumbra Inc (PEN) reported a strong revenue growth of 12.9% year over year for Q4 2024, reaching $321.3 million, with a 13% growth on a constant currency basis.
- The US thrombectomy business showed significant growth, with sales increasing by 27.3% year over year, driven by a 41% growth in the US VTE franchise.
- Penumbra Inc (PEN) introduced nine new products to the US market, including advancements in their CAVT portfolio, which contributed to their strong market position.
- The company achieved a gross margin of 67.4% in Q4 2024, an improvement of 170 basis points from the previous year, indicating strong profitability.
- Penumbra Inc (PEN) is on track to achieve a gross margin profile over 70% by the end of 2026, supported by favorable product mix and operational efficiencies.
- International revenue declined by 9.4% adjusted and 9.1% in constant currency, primarily due to a significant decrease in China revenue.
- The company faced a $5.8 million reserve related to Italian payback legislation, impacting financial results.
- Penumbra Inc (PEN) experienced a one-time $33.4 million Immersive Healthcare inventory write-off, affecting the gross margin for the year.
- The guidance for 2025 revenue growth is set at 12% to 14%, which some analysts questioned given the headwinds faced in 2024.
- The company has not yet submitted the Thunderbolt technology for FDA approval, which could impact future growth projections.
Good afternoon. My name is Rob, and I will be your conference operator today.
At this time, I would like to welcome everyone to Penumbra's fourth-quarter 2024 conference call.
(Operator Instructions)
I would like to introduce Ms. Cecilia Furlong, Business Development and Investor Relations for Penumbra. Ms. Furlong, you may begin your conference.
Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for the fourth quarter and full year 2024.
A copy of the press release and financial tables, which includes a GAAP to non-GAAP reconciliation, can be viewed under the Investors tab on our company website at www.penumbrainc.com. During the course of this conference call, the company will make forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
